Navigation Links
Telik Announces First Quarter 2011 Financial Results
Date:5/16/2011

PALO ALTO, Calif., May 16, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today reported financial results for the first quarter ended March 31, 2011.  The net loss for the quarter ended March 31, 2011 was $3.7 million, or $0.07 per share, compared with a net loss of $5.3 million, or $0.10 per share, for the same period in 2010.

Total research and development expenses (R&D) in the first quarter of 2011 were $1.7 million, compared to $2.8 million for the same period in 2010.  The decrease in R&D expenses was primarily due to lower headcount and related costs, lower clinical development expenditures and lower facility allocation cost as a result of the relocation of our corporate offices in the fourth quarter of 2010.

Total general and administrative expenses (G&A) in the first quarter of 2011 were $2.0 million, compared to $2.6 million for the same period in 2010.  The decrease in G&A expenses was primarily due to lower stock-based compensation expense, lower headcount and lower facility allocation cost.

The company anticipates its 2011 net cash utilization to be in the range of $14.0 million to $15.0 million, with total operating expenses in the range of $13.0 million to $15.0 million of which approximately 53% is expected to be R&D expense and 47% G&A expense.

As of March 31, 2011, cash, cash equivalents, restricted cash and investments totaled $20.2 million, compared with $24.1 million for the quarter ended December 31, 2010.

Telik continues to focus on advancing the clinical development of TELINTRA® for Myelodysplastic Syndrome (MDS) and other blood disorders.  Ongoing clinical trials for TELINTRA include a Phase 1 multicenter, dose escalation study in combination with lenalidomide (Revlimid®) in patients with low to intermediate-1 risk MDS and a Phase 2 randomized
'/>"/>

SOURCE Telik, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Telik Announces Presentation of New Data on the Characterization of Novel Ezatiostat (TELINTRA®, TLK199) Analogs at American Association for Cancer Research Annual Meeting
2. Telik Announces Presentation and Webcast at 10th Annual Needham Healthcare Conference
3. Telik Announces Fourth Quarter and 2010 Year End Financial Results and 2011 Financial Guidance
4. Telik Announces Presentation and Webcast at 13th Annual BIO CEO & Investor Conference
5. Telik Announces Presentation at American Society of Hematology Annual Meeting
6. Telik Announces Third Quarter 2010 Financial Results
7. Telik Awarded $1.2 Million in Grants for Qualifying Therapeutic Development Projects
8. Telik Announces Publication of Review Focused on the Inhibition of the Enzyme GSTP1-1 as a Target for New Cancer Treatments
9. Telik Announces Publication of a Case Report of a Sustained Hematologic Response in Myelodysplastic Syndrome Following an Abbreviated Exposure to Oral Telintra(R) (Ezatiostat HCl)
10. Telik Announces Fourth Quarter and 2009 Year End Financial Results and 2010 Financial Guidance
11. Telik Announces Initiation of Phase 1 Clinical Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets in Combination With Lenalidomide (Revlimid(R)) in Patients With Myelodysplastic Syndrome (MDS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014 /CNW/ - ... being recalled after Health Canada tests confirmed it contains ... risks (beta-methylphenethylamine and phenylpropylmethylamine). The distributor, Empire Health Distribution ... the product from retail stores across Canada ... purposes, including for weight loss and increased energy. ...
(Date:12/24/2014)...  Novastem, a leader in regenerative medicine, announces ... study for ischemic stroke at Clinica Santa Clarita. ... account for 87 percent of all stroke cases. ... study, entitled "Internal Research Protocol in Combination Therapy ... and Intrathecal Administration of Neural Stem Cells in ...
(Date:12/24/2014)... DUBLIN , Dec. 24, 2014  Actavis ... that the Company has received a complete response ... (FDA) for its New Drug Application (NDA) for ... for the treatment of hypertension.   Photo ... we are disappointed in the receipt of a ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4
... Fla., Oct. 9 VitalRemedyMD, a physician-established company, ... improve the quality of traditional healthcare. "We are ... of Fresenius, armamentarium in helping patients with chronic ... VitalRemedyMD. A state-of-the-art medical food, VitalProteinRx is designed ...
... , ... Healthcare and HHC Nutrition Services will pay the United States $1.375 ... kickbacks and assistance under the guise of a sham durable medical ... that McKesson Corp., and its affiliate MediNet Corp. provided the kickbacks ...
Cached Medicine Technology:Fresenius Medical Care, N.A. Has Selected VitalRemedyMD's VitalProteinRx(TM) As Its Bar of Choice for Protein Replacement in Dialysis Patients 2Harborside Healthcare to Pay U.S. $1.375 Million to Resolve Allegations of Kickbacks and Sham Durable Medical Services 2
(Date:12/25/2014)... (PRWEB) December 26, 2014 This is ... of the global Sterilizers industry with a focus on ... the market status of the Sterilizers manufacturers and is ... and individuals interested in the industry. This report provides ... applications and manufacturing technology. In this part, the report ...
(Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) ... on the current treatment landscape, unmet needs, current ... market. Stivarga is a drug which is used ... Boehringer Ingelheim is developing nintedanib (BIBF-1120), an orally ... CRC in the US, Europe, and Japan. The ...
(Date:12/25/2014)... December 25, 2014 Product liability lawsuits ... hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward ... an Order issued in the U.S. District Court, Northern ... convene an open conference on January 7, 2015, at ... Courthouse in West Palm Beach, Florida. The Conference is ...
(Date:12/25/2014)... December 26, 2014 Recently, iFitDress.com, the popular ... women, has announced its new selection of black one-shoulder ... on sale now; they are available at discounted prices, up ... “The promotion will last for three weeks only. You know, ... Those who are interested in our new items can visit ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 The short film ... was created in honor of a true 9/11 hero, Welles ... film festivals including the 24 hours of Nuremberg International Short ... Bangladesh. , Actress, screenwriter and director Luciana Lagana ... this film together with her husband, Gregory Graham ...
Breaking Medicine News(10 mins):Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3
... today announced,that it has finalized an agreement with U.K.-based ... with wound dressings,manufactured by AMS., Through this collaboration, ... testing of the use of GLYC-101 with AMS, wound ... phase of testing gives rise to,favorable results, or generates ...
... Professor Ian Frazer has won the 2008 Prime Minister,s ... UQ,s Diamantina Institute for Cancer, Immunology and Metabolic Medicine, ... Rudd at a special ceremony in the Great Hall, ... , The Prime Minister,s Prize for Science is the ...
... Pa., Oct. 17 Level III Trauma,Center Accreditation ... in,Pennsylvania for the period from November 1, 2008 ... South Jackson Street, Pottsville, PA, The Pennsylvania ... by the Emergency Medical Services Act (Act 1985-45).,The ...
... Regional Expansion With Mobile Healthy,Living Experience in Greater ... of Grains brand announced today,their expansion into the ... a Mobile Healthy Living Experience at select Hannaford ... simple, better decisions,to improve their lifestyle and diet. ...
... Part of Larger Health and,Nutrition Program, HACKETTSTOWN, ... is proud to be the first confectionery company ... (GDA) nutrition labeling on,all of its chocolate, non-chocolate ... redesigned to feature new graphics on the front ...
... for Joint-Pain Sufferers Who are Confused and Concerned, About ... Reveals Truth About Makeup of Joint ... 17 A new Web site,dedicated to helping women fight ... to help joint-pain sufferers take control of,their lives with a ...
Cached Medicine News:Health News:Glycotex Finalizes Collaboration Agreement with Advanced Medical Solutions 2Health News:Glycotex Finalizes Collaboration Agreement with Advanced Medical Solutions 3Health News:PM's science prize for Ian Frazer 2Health News:Level III Trauma Center Accreditation Status for Pennsylvania 2Health News:World of Grains(TM) - The Cookie That's One Bite Better Comes to a Store Near You 2Health News:World of Grains(TM) - The Cookie That's One Bite Better Comes to a Store Near You 3Health News:Mars First Confectionery Company to Launch Front-of-Pack Nutrition Labeling Globally 2Health News:Mars First Confectionery Company to Launch Front-of-Pack Nutrition Labeling Globally 3Health News:Mars First Confectionery Company to Launch Front-of-Pack Nutrition Labeling Globally 4Health News:Mars First Confectionery Company to Launch Front-of-Pack Nutrition Labeling Globally 5Health News:www.Joyn7030.com, A New Web Site Dedicated to Helping Women Fight Joint Pain, Launches 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: